These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8102399)

  • 21. Olsalazine in the treatment of mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind, clinical trial.
    Feurle GE; Theuer D; Velasco S; Barry BA; Wördehoff D; Sommer A; Jantschegk Y; Kruis W
    Scand J Gastroenterol Suppl; 1988; 148():38-9. PubMed ID: 3067338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olsalazine in patients intolerant of sulphasalazine.
    Ireland A; Jewell DP
    Scand J Gastroenterol; 1987 Nov; 22(9):1038-40. PubMed ID: 2892247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition.
    Hetzel DJ; Shearman DJ; Labrooy J; Bochner F; Imhoff DM; Gibson GE; Fitch RJ; Hecker R; Rowland R
    Scand J Gastroenterol Suppl; 1988; 148():61-9. PubMed ID: 3067339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis.
    Fleig WE; Laudage G; Sommer H; Wellmann W; Stange EF; Riemann J
    Digestion; 1988; 40(3):173-80. PubMed ID: 2906888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
    Rao SS; Cann PA; Holdsworth CD
    Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM; Greenberg GR
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulfasalazine-induced impotence: a beneficial resolution with olsalazine?
    Ireland A; Jewell DP
    J Clin Gastroenterol; 1989 Dec; 11(6):711. PubMed ID: 2573629
    [No Abstract]   [Full Text] [Related]  

  • 30. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.
    Singer MV; Schmausser H; Schönfeld G
    Hepatogastroenterology; 2006; 53(69):317-21. PubMed ID: 16795963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
    Courtney MG; Nunes DP; Bergin CF; O'Driscoll M; Trimble V; Keeling PW; Weir DG
    Lancet; 1992 May; 339(8804):1279-81. PubMed ID: 1349676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.
    Wadworth AN; Fitton A
    Drugs; 1991 Apr; 41(4):647-64. PubMed ID: 1711964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
    Birketvedt GS; Berg KJ; Fausa O; Florholmen J
    Inflamm Bowel Dis; 2000 Nov; 6(4):275-9. PubMed ID: 11149559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.